Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Phase 2 Recruiting
70 enrolled
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Phase 2 Recruiting
60 enrolled
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Phase 1 Recruiting
32 enrolled
NETTER-3
Phase 3 Recruiting
240 enrolled
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
Phase 2/3 Recruiting
193 enrolled
The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support
Recruiting
25 enrolled
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Phase 2 Recruiting
100 enrolled
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Phase 2 Recruiting
12 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
Studies on Tumors of the Thyroid
Recruiting
2,500 enrolled
Evaluation and Treatment of Neurosurgical Disorders
Recruiting
5,000 enrolled
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Recruiting
2,415 enrolled
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Recruiting
1,150 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
LuCa-MERIT-1
Phase 1 Recruiting
320 enrolled
LUPARPED
Phase 1/2 Recruiting
25 enrolled
Tumor HI
Phase 3 Recruiting
16 enrolled
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Phase 2 Recruiting
48 enrolled
Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery
Phase NA Recruiting
70 enrolled
MK-6482-015
Phase 2 Recruiting
322 enrolled 3 FDA
DeLLight
Phase 2 Recruiting
60 enrolled
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Phase 1 Recruiting
104 enrolled
DDAVP for Pituitary Adenoma
Phase NA Recruiting
22 enrolled
Natural History Study of Parathyroid Disorders
Recruiting
3,000 enrolled
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Phase 1/2 Recruiting
49 enrolled
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Phase NA Recruiting
21 enrolled
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Phase 1 Recruiting
6 enrolled
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Phase 1/2 Recruiting
138 enrolled
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Phase 1/2 Recruiting
56 enrolled
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
Phase 2/3 Recruiting
400 enrolled
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Recruiting
2,000 enrolled
TRIDENT-1
Phase 1/2 Recruiting
500 enrolled 5 FDA
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Phase 2 Recruiting
200 enrolled
Diagnosing and Treating Low Blood Sugar Levels
Recruiting
1,500 enrolled
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Phase 2 Recruiting
130 enrolled
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Recruiting
150 enrolled
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Recruiting
5,000 enrolled
Diagnosis of Pheochromocytoma
Phase 1 Recruiting
3,000 enrolled
ACTION-1
Phase 3 Recruiting
338 enrolled
INDIGO
Phase NA Recruiting
51 enrolled
Natural History Study of Children and Adults With Medullary Thyroid Cancer
Recruiting
259 enrolled
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Phase 1 Recruiting
70 enrolled
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 Recruiting
320 enrolled
PRO-NEM1
Recruiting
297 enrolled
STELLAR-311
Phase 2/3 Recruiting
440 enrolled
Pituitary Tumor Surveillance: Pathogenic Correlation
Recruiting
1,250 enrolled
Natural History of Familial Carcinoid Tumor
Recruiting
1,600 enrolled
PRRT
Recruiting
50 enrolled
The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma
Recruiting
3,772 enrolled
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Phase 1 Recruiting
10 enrolled